Abstract
Carcinoma of the prostate has historically been associated with the bleeding diathesis which accompanies disseminated intravascular coagulation. We have performed a prospective study into the prevalence of coagulopathy in patients with untreated prostate cancer using matched patients with benign prostatic hypertrophy (BPH) as controls. Haemostatic activation was assessed by measuring fibrinopeptide A (FpA) by an ELISA and D-dimer by a latex agglutination assay. FpA and D-dimer levels were correlated with serum prostate specific antigen (PSA) and bone scan status. Of the cancer patients, 40% had elevated FpA, levels being higher in those with bone scan positive disease (P < 0.05). D-dimer was detectable in 24% of those with prostate cancer but in none with BPH. Neither FpA nor D-dimer were related to serum PSA but D-dimer appeared to be a predictor of bone scan status with a positive predictive value of 91%. It is concluded that changes compatible with subclinical DIC are common in patients presenting with prostate cancer and that measurement of FpA and D-dimer may have roles as tumour markers in this disease.
Full text
PDF




Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Al-Mondhiry H., Manni A., Owen J., Gordon R. Hemostatic effects of hormonal stimulation in patients with metastatic prostate cancer. Am J Hematol. 1988 Jul;28(3):141–145. doi: 10.1002/ajh.2830280303. [DOI] [PubMed] [Google Scholar]
- Auger M. J., Galloway M. J., Leinster S. J., McVerry B. A., Mackie M. J. Elevated fibrinopeptide A levels in patients with clinically localised breast carcinoma. Haemostasis. 1987;17(6):336–339. doi: 10.1159/000215766. [DOI] [PubMed] [Google Scholar]
- Baker W. F., Jr Clinical aspects of disseminated intravascular coagulation: a clinician's point of view. Semin Thromb Hemost. 1989 Jan;15(1):1–57. doi: 10.1055/s-2007-1002689. [DOI] [PubMed] [Google Scholar]
- Bick R. L. Disseminated intravascular coagulation and related syndromes: a clinical review. Semin Thromb Hemost. 1988 Oct;14(4):299–338. doi: 10.1055/s-2007-1002793. [DOI] [PubMed] [Google Scholar]
- Blombäck M., Hedlund P. O., Säwe U. Changes in blood coagulation and fibrinolysis in patients on different treatment regimens for prostatic cancer. Predictors for cardiovascular complications? Thromb Res. 1988 Jan 1;49(1):111–121. doi: 10.1016/0049-3848(88)90364-7. [DOI] [PubMed] [Google Scholar]
- Brozna J. P. Cellular regulation of tissue factor. Blood Coagul Fibrinolysis. 1990 Oct;1(4-5):415–426. doi: 10.1097/00001721-199010000-00009. [DOI] [PubMed] [Google Scholar]
- Büller H. R., Boon T. A., Henny C. P., Dabhoiwala N. F., ten Cate J. W. Estrogen-induced deficiency and decrease in antithrombin III activity in patients with prostatic cancer. J Urol. 1982 Jul;128(1):72–74. doi: 10.1016/s0022-5347(17)52762-7. [DOI] [PubMed] [Google Scholar]
- Carr J. M., McKinney M., McDonagh J. Diagnosis of disseminated intravascular coagulation. Role of D-dimer. Am J Clin Pathol. 1989 Mar;91(3):280–287. doi: 10.1093/ajcp/91.3.280. [DOI] [PubMed] [Google Scholar]
- Chybowski F. M., Keller J. J., Bergstralh E. J., Oesterling J. E. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991 Feb;145(2):313–318. doi: 10.1016/s0022-5347(17)38325-8. [DOI] [PubMed] [Google Scholar]
- Drewinko B., Cobb P., Guinee V., Giacco G., Trujillo J. M., von Eschenbach A. Untreated prostatic carcinoma is not associated with frequent thrombohemorrhagic disorders. Urology. 1987 Jul;30(1):11–17. doi: 10.1016/0090-4295(87)90562-0. [DOI] [PubMed] [Google Scholar]
- Gordon S. G., Franks J. J., Lewis B. Cancer procoagulant A: a factor X activating procoagulant from malignant tissue. Thromb Res. 1975 Feb;6(2):127–137. doi: 10.1016/0049-3848(75)90018-3. [DOI] [PubMed] [Google Scholar]
- Henriksson P., Blombäck M., Bratt G., Edhag O., Eriksson A. Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy. Thromb Res. 1986 Dec 15;44(6):783–791. doi: 10.1016/0049-3848(86)90024-1. [DOI] [PubMed] [Google Scholar]
- Hienert G., Kirchheimer J. C., Pflüger H., Binder B. R. Urokinase-type plasminogen activator as a marker for the formation of distant metastases in prostatic carcinomas. J Urol. 1988 Dec;140(6):1466–1469. doi: 10.1016/s0022-5347(17)42074-x. [DOI] [PubMed] [Google Scholar]
- Kirchheimer J., Köller A., Binder B. R. Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta. 1984 Feb 14;797(2):256–265. doi: 10.1016/0304-4165(84)90129-6. [DOI] [PubMed] [Google Scholar]
- Myers T. J., Rickles F. R., Barb C., Cronlund M. Fibrinopeptide A in acute leukemia: relationship of activation of blood coagulation to disease activity. Blood. 1981 Mar;57(3):518–525. [PubMed] [Google Scholar]
- Nandi S. R., Knox J. Carcinoma of prostate: the effect of oestrogens on blood viscosity. Br J Clin Pract. 1986 Sep;40(9):383–385. [PubMed] [Google Scholar]
- Nanninga P. B., van Teunenbroek A., Veenhof C. H., Büller H. R., ten Cate J. W. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost. 1990 Nov 30;64(3):361–364. [PubMed] [Google Scholar]
- Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
- Rader E. S. Hematologic screening tests in patients with operative prostatic disease. Urology. 1978 Mar;11(3):243–246. doi: 10.1016/0090-4295(78)90124-3. [DOI] [PubMed] [Google Scholar]
- Rickles F. R., Edwards R. L., Barb C., Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer. 1983 Jan 15;51(2):301–307. doi: 10.1002/1097-0142(19830115)51:2<301::aid-cncr2820510223>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- Sack G. H., Jr, Levin J., Bell W. R. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 1977 Jan;56(1):1–37. [PubMed] [Google Scholar]
- Sun N. C., McAfee W. M., Hum G. J., Weiner J. M. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol. 1979 Jan;71(1):10–16. doi: 10.1093/ajcp/71.1.10. [DOI] [PubMed] [Google Scholar]
- Szczepański M., Bardadin K., Zawadzki J., Pypno W. Procoagulant activity of gastric, colorectal, and renal cancer is factor VII-dependent. J Cancer Res Clin Oncol. 1988;114(5):519–522. doi: 10.1007/BF00391504. [DOI] [PubMed] [Google Scholar]
- Theiss W., Beller F. K. Stilbestrol-augmented disseminated intravascular coagulation in rats after infusion of endotoxin. Am J Obstet Gynecol. 1973 Mar 15;115(6):775–782. doi: 10.1016/0002-9378(73)90519-x. [DOI] [PubMed] [Google Scholar]
- van Deijk W. A., van Dam-Mieras M. C., Muller A. D. Activation of factor VII in patients with carcinoma of the prostate. A preliminary report. Haemostasis. 1983;13(3):198–200. doi: 10.1159/000214727. [DOI] [PubMed] [Google Scholar]